Feasibility of a multiplex flow cytometric bead immunoassay for detection of anti-epoetin alfa antibodies

Clinical and Vaccine Immunology

Volumn 14, Issue 9, 2007, Pages 1165-1172

  Ferbas, John ^a   Thomas, John ^a   Hodgson, John ^b   Gaur, Amitabh ^b   Casadevall, Nicole ^c   Swanson, Steven J ^a  

^a AMGEN INC   (United States)

^b BD BIOSCIENCES   (United States)

^c HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPOETIN ALFA ANTIBODY; ERYTHROPOIETIN ANTIBODY; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ACCURACY; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ERYTHROCYTE APLASIA; FEASIBILITY STUDY; FLOW CYTOMETRY; HUMAN; IMMUNOASSAY; MULTIPLEX FLOW CYTOMETRIC BEAD IMMUNOASSAY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION;

AUTOANTIBODIES; EPOETIN ALFA; FEASIBILITY STUDIES; FLOW CYTOMETRY; HUMANS; IMMUNOASSAY; MICROSPHERES; RECOMBINANT PROTEINS; RED-CELL APLASIA, PURE;

EID: 34948895123     PISSN: 15566811     EISSN: None     Source Type: Journal    
DOI: 10.1128/CVI.00157-07     Document Type: Article

References (26)

1. Bennett, C. L., D. Cournoyer, K. R. Carson, J. Ressert, S. Luminari, A. M. Evens, F. Locatelli, S. M. Belknap, J. M. McKoy, E. A. Lyons, B. Kim, R. Sharma, S. Costello, E. B. Toffelmire, G. A. Wells, H. A. Messner, P. R. Yarnold, S. M. Trifilio, D. W. Raisch, T. M. Kuzel, A. Nissenson, L. C. Lim, M. S. Tallman, and N. Casadevall. 2005. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) project. Blood 106:3343-3347.
2. Bonneld, T. L., N. John, B. P. Barna, M. S. Kavuru, M. J. Thomassen, and B. Yen-Lieberman. 2005. Multiplexed particle-based anti-granulocyte macrophage colony stimulating factor assay used as pulmonary diagnostic test. Clin. Diagn. Lab. Immunol. 12:821-824.
3. Boven, K., J. Knight, F. Bader, J. Ressert, K. U. Eckardt, and N. Casadevall. 2005. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol. Dialysis Transplant. 20:iii33-iii40.
4. Boven, K., S. Stryker, J. Knight, A. Thomas, M. van Regenmortel, D. M. Kemeny, D. Power, J. Rossert, and N. Casadevall. 2005. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int. 67:2346-2353.
5. Casadevall, N., J. Nataf, B. Viron, A. Kolta, J. J. Kiladjian, P. Martin-Dupont, P. Michaud, T. Papo, V. Ugo, I. Teyssandier, B. Varet, and P. Mayens. 2002. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346:469-475.
6. Casadevall, N., and J. Rossert. 2005. Importance of biologic follow-ons: experience with EPO. Best Pract. Res. Clin. Hematol. 18:381-387.
7. Dias, D., J. Van Doren, S. Schlottmann, S. Kelly, D. Puchalski, W. Ruiz, P. Boerckel, J. Kessler, J. M. Antonello, T. Green, M. Brown, J. Smith, N. Chirmule, E. Barr, K. U. Jansen, and M. T. Esser. 2005. Optimization and validation of a multiplexed Luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin. Diagn. Lab. Immunol. 12:959-969.
8. Dighiero, G., B. Guilbert, and S. Avrameas. 1982. Naturally occurring antibodies against nine common antigens in humans sera. II. High incidence of monoclonal Ig exhibiting antibody activity against actin and tubulin and sharing antibody specificities with natural antibodies. J. Immunol. 128:2788-2792.
9. Guilbert, B., G. Dighiero, and S. Avrameas. 1982. Naturally occurring antibodies against nine common antigens in human sera. I. Detection, isolation, and characterization. J. Immunol. 128:2779-2787.
10. Hashida, S., M. Imagawa, S. Inoue, K. H. Ruan, and E. Ishikawa. 1984. More useful maleimide compounds for the conjugation of Fab' to horserad-ish peroxidase through thiol groups in the hinge. J. Appl. Biochem. 6:56-63.
11. Koren, E., L. A. Zuckerman, and A. R. Mire-Sluis. 2002. Immune responses to therapeutic proteins in humans: clinical significance, assessment and prediction. Curr. Pharm. Biotechnol. 3:349-360.
12. Locatelli, F., P. Aljama, P. Barany, B. Canaud, F. Carrera, K. U. Eckardt, I. C. MacDougall, A. Macleod, W. H. Horl, A. Wiecek, and S. Cameron. 2004. Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here? Nephrol. Dialysis Transplant. 19:288-293.
13. Louet, S. 2003. Lessons from Eprex for biogeneric firms. Nat. Biotechnol. 21:956-957.
14. Mason, S., S. La, D. Mytych, S. J. Swanson, and J. Ferbas. 2003. Validation of the BIACORE 3000 platform for detection of antibodies against erythropoietic agents in human serum samples. Curr. Med. Res. Opin. 19:651-659.
15. Mire-Sluis, A. R., Y. C. Barrett, V. Devanarayan, E. Koren, H. Liu, M. Maia, T. Parish, G. Scott, G. Shankar, and E. Shores. 2004. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 289:1-16.
16. Morgan, E., R. Varro, H. Sepulveda, J. A. Ember, J. Apgar, J. Wilson, L. Lowe, R. Chen, L. Shivraj, A. Agadir, R. Campos, D. Ernst, and A. Gaur. 2004. Cytometric bead array: a multiplexed assay platform with applications in various areas of biology. Clin. Immunol. 110:252-266.
17. Porter, S. 2001. Human immune response to recombinant human proteins. J. Pharm. Sci. 90:1-11.
18. Rossert, J. 2005. Erythropoietin-induced, antibody mediated pure red cell aplasia. Eur. J. Clin. Investig. 35(Suppl. 3):95-99.
19. Schellekens, H., and W. Jiskoot. 2006. Eprex-associated pure red cell aplasia and leachates. Nat. Biotechnol. 24:613-614.
20. Shovman, O., B. Gilburd, O. Barzilai, E. Shinar, B. Larida, G. Zandma-Goddard, S. R. Binder, and Y. Shoenfeld. 2005. Evaluation of the BioPlex 2200 ANA screen: analysis of 510 healthy subjects: incidence of natural/predictive autoantibodies. Ann. N. Y. Acad. Sci. 1050:380-388.
21. Suzanne, H., J. Wim, J. A. C. Daan, and S. Huub. 2006. Reaction to the paper: interaction of polysorbate 80 with erythropoietin: a case study in protein surfactant Interactions. Pharm. Res. V 23:641-642.
22. Swanson, S. J., J. Ferbas, P. Mayeux, and N. Casadevall. 2004. Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron Clin. Pract. 96:c88-c95.
23. Swanson, S. J., D. Mytych, and J. Ferbas. 2002. Use of biosensors to monitor the immune response. Dev. Biol. 109:71-78.
24. Thorpe, R., and S. J. Swanson. 2005. Assays for detecting and diagnosing antibody-mediated pure red cell aplasia (PRCA): an assessment of available procedures. Nephrol. Dialysis Transplant. 20:iv16-iv22.
25. Twining, S. S., H. F. Lehmann, and M. Z. Atassi. 1980. The antibody response to myoglobin is independent of the immunized species: analysis in terms of replacements in the antigenic sites and in environmental residues of the cross-reactions of fifteen myoglobins with sperm-whale myoglobin antisera raised in different species. Biochem. J. 191:681-697.
26. Wei, X., S. J. Swanson, and S. Gupta. 2004. Development and validation of a cell-based bioassay for the detection of neutralizing antibodies against recombinant human erythropoietin in clinical studies. J. Immunol. Methods 293:115-126.